Read More

Janssen To Discontinue Internal Development Of Cidara Therapeutics-Partnered Influenza Candidate

Cidara Therapeutics Inc (NASDAQ: CDTX) provided an update on the status of its ongoing CD388 program for the prevention of influenza A and B under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a part of Johnson & John

CDTX